Abstract
Regulators of G protein signaling (RGS) act as guanosine triphosphatase activating proteins to accelerate guanosine triphosphate hydrolysis of the G protein α subunit, leading to the termination of the G protein-coupled receptor (GPCR) downstream signaling pathway. RGS16, which is expressed in a number of cells and tissues, belongs to one of the small B/R4 subfamilies of RGS proteins and consists of a conserved RGS structural domain with short, disordered amino- and carboxy-terminal extensions and an α-helix that classically binds and de-activates heterotrimeric G proteins. However, with the deepening of research, it has been revealed that RGS16 protein not only regulates the classical GPCR pathway, but also affects immune, inflammatory, tumor and metabolic processes through other signaling pathways including the mitogen-activated protein kinase, phosphoinositide 3-kinase/protein kinase B, Ras homolog family member A and stromal cell-derived factor 1/C-X-C motif chemokine receptor 4 pathways. Additionally, the RGS16 protein may be involved in the Hepatitis B Virus -induced inflammatory response. Therefore, given the continuous expansion of knowledge regarding its role and mechanism, the structure, characteristics, regulatory mechanisms and known functions of the small RGS proteinRGS16 are reviewed in this paper to prepare for diagnosis, treatment, and prognostic evaluation of different diseases such as inflammation, tumor, and metabolic disorders and to better study its function in other diseases.
Introduction
G protein-coupled receptors (GPCRs) are the largest superfamily of membrane proteins that control most cellular signaling and regulate key biological functions, including immune, inflammatory, oncological, and metabolic processes, by coupling to G proteins to transmit extracellular signals into the cell (Syrovatkina et al., 2016). In the resting state, heterotrimeric G proteins, which consist of α, β and γ subunits, bind to guanosine diphosphate (GDP). (). In the state of external stimulation, GPCRs act as guanine nucleotide exchange factors (GEFs), facilitating the exchange of guanosine triphosphate (GTP) with GDP on Gα, and the activated GTP-Gα dissociates from the Gβγ dimer, undergoing conformational changes and regulating downstream effector proteins (). The α subunit is enzymatically active, and can catalyze the hydrolysis of GTP to GDP, after which Gα reassociates with Gβγ and returns to the resting state. Depending on the structural and functional differences, Gα subunits, including Gs, Gi/o, Gq/11, G12/13, etc., can mediate different signaling pathways (Soundararajan et al., 2008).
The regulators of G protein signaling (RGS) proteins, , which were discovered at the end of the 20th century, are a family of molecularly diverse and multifunctional proteins and are capable of binding to G protein-activated α-subunits, activating guanosine triphosphatases (GTPases) and accelerating the hydrolysis of GTP (>1,000-fold), thereby terminating the G protein signaling pathway (). Dysregulation of RGS expression is involved in a variety of diseases, including cancer, and cardiovascular and neurodegenerative diseases (). According to the homology of the amino acid sequence and the different external signal domains, the typical RGS proteins can be divided into four groups: A/RZ, B/R4, C/R7 and D/R12 ().
Members of the B/R4 subfamily include RGS1-5, 8, 13, 16, 18 and 21, which are the smallest RGS proteins except for RGS3 (). RGS16, also known as A28-RGS14 or RGS-R, is expressed in a variety of tissues, such as the retina, pituitary gland, bone marrow and liver (; ; Snow et al., 1998a). It has been demonstrated that the RGS16 protein not only regulates GPCR through classical signaling pathways, but also regulates tumor and inflammatory diseases through mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt), Ras homolog family member A (Rho A) , stromal cell-derived factor 1 (SDF-1)/C-X-C motif chemokine receptor 4(CXCR4) and other signaling pathways (; ; ). The association of the RGS16 protein with immune, inflammatory, tumor and metabolic disorders has been well established, and the RGS16 protein may also be involved in hepatitis B -induced inflammatory response. Therefore, the present review summarizes the structure, characteristics, regulatory mechanisms and known functions of RGS16 in different diseases such as immunity, inflammation, tumors and metabolic disorders.
RGS protein family
At the end of the 20th century, a family of G protein signaling regulatory proteins (RGS) was identified in yeast, C. elegans and mammals (; ; ), and these represent a family of intracellular proteins of different molecular sizes, structures and multifunctionality that negatively regulate the signaling of GPCRs and heterotrimeric G proteins in a canonical manner (). RGS proteins control the strength and duration of the G protein-mediated signaling pathway, and they act as GTPase activating proteins (GAPs) which can accelerate the hydrolysis of the active Gα-GTP form of GTP, and then convert it into the inactive Gα-GTP form. This leads to the termination of the downstream G protein signaling pathway (Figure 1) (; ).
FIGURE 1
There are >30 RGS proteins in mammalian cells, all belonging to one superfamily, and all members have a shared, homologous, and highly conserved RGS domain or “RGS box” consisting of 120 amino acid residues (). The RGS structural domain or “RGS box” mainly functions as GAPs (). However, it has also been reported that deletion of the RGS region resulted in the loss of GAP activity, while the binding of the Gα subunit was structurally unchanged (Ross and Wilkie, 2000; Sjögren et al., 2010; ). Notably, there are different sequences on either side of the conserved RGS region, and this difference in sequence of the flanking regions may be a determinant of the functional specificity of RGS proteins. For instance, the RGS12 and RGS14 proteins share the RBD structural domain and Go Loco motif, through which both RGS12 and RGS14 interact with activated small G proteins, such as H-Ras-GTP and Rap-2-GTP (Willard et al., 2009; Shu et al., 2010). Unlike RGS14, RGS12 also possesses two additional structural domains including the PDZ and PTB domains. The C-terminus of C-X-C motif chemokine receptor 2 is bound by the PDZ domain (Snow et al., 1998b), while neuronal N-type calcium channels are involved in PTB domain interactions (Schiff et al., 2000; Richman et al., 2005). At the same time, both PDZ/PTB domains markedly attenuate extracellular regulated protein kinases (ERK) phosphorylation downstream of platelet derived growth factor-βreceptor (Sambi et al., 2006). This indicates that the sequence of the flanking region of the RGS proteins does serve an indispensable role in their function.
In recent years, more and more RGS proteins have been identified as research progresses. Based on the homology of amino acids sequences and the presence of external signaling domains, RGS proteins can be further divided into different subfamilies (Xie et al., 2016) (Figure 2). The RGS subfamily binds to different cognate Gα substrates through a unique stereochemical structure. The RGS subfamilies B/R4, C/R7 and D/R10 are involved in Gα i/o (; Snow et al., 1998b; ; ), the B/R4 subfamily is also involved in Gαq (; Tany et al., 2022), the F/GEF subfamily is involved in Gα12/13 (; Siehler, 2009), and the A/RZ subfamily is involved in Gαz and Gαi (Wang et al., 1998; Wang et al., 2002). The B/R4 subfamily is the largest subfamily in the RGS protein classification, but they are the smallest RGS proteins in terms of size (). This family is also the simplest of all RGS proteins in terms of structure and function. Unlike the B/R4 family, other families have multiple domains that interact with multiple proteins besides the Gα subunit and have more complex cellular effects ().
FIGURE 2
Heterotrimeric G proteins catalyze the exchange of GTP on Gα with GDP upon conformational changes in GPCR, and the dissociation of activated GTP-Gα from Gβγ dimers to regulate downstream effector proteins that in turn generate a number of cellular responses, including cell proliferation, cell differentiation, plasma membrane transport, cell motility, and embryonic development (; Wang et al., 2020). In this process RGS proteins control the strength and duration of G protein-mediated signaling pathways, leading to the termination of downstream signaling pathways, thus affecting these cellular processes (; O'Brien et al., 2019). They are involved in almost every aspect of cell biology and cause reactions in every organ system involved in disease processes such as cancer (; ), inflammation (Suurväli et al., 2015; Xie et al., 2016), cardiovascular processes (; ), immunity and even depression (). For instance, RGS1 is highly expressed in multiple myeloma and is a promising target for the treatment of multiple myeloma as a prognostic marker by desensitizing or stimulating receptor activity, thereby altering the GPCR signaling pathway and its downstream activity (Roh et al., 2017). Absence of RGS5 enhances angiotensin Ⅱ-induced blood pressure elevation and vasoconstriction, thereby preventing anxiety-like behavior and angiotensin Ⅱ-induced depression-like behavior ().
The classical biological role of RGS proteins at the cellular level is acting as GAPs to regulate the GPCR signaling pathway (). For example, RGS18, a myeloid-specific regulator of G protein signaling molecules highly expressed in megakaryocytes, acts as a GAP to regulate megakaryocyte differentiation and chemotaxis in mammalian and yeast cells in vitro via the GPCR signaling pathway (Yowe et al., 2001). In addition, RGS2, RGS4 and RGS5 act as GAPs attenuating the G protein signaling pathway in vascular and cardiac myocytes as well as in cells of the kidney and autonomic nervous system, which may be a possible strategy for the treatment and prevention of hypertension and cardiovascular disease (). Nevertheless, in addition to acting as GAPs, RGS proteins are also regulated through non-classical pathways. For example, RGS5 reduces the proliferation of human ovarian cancer-derived primary endothelial cells via the MAPK/ERK signaling pathway under hypoxic conditions (Wang et al., 2019). RGS10, the most highly expressed protein in peripheral macrophages, inhibits the expression of cyclooxygenase-2 and tumor necrosis factor α (TNFα) through a G protein non-dependent mechanism to regulate inflammatory signaling in microglia and ovarian cancer cells (). RGS1 gene silencing inhibits the inflammatory response and angiogenesis in rheumatoid arthritis rats by suppressing the toll-like receptor (TLR) 3 signaling pathway (). Overall, the RGS protein family serves a critical role in the regulation of G protein-mediated pathways and many pathophysiological processes in various tissues through both classical and non-classical pathways. Synchronously, the RGS16 protein has been predicted to serve a central role in immune and inflammatory responses in addition to being a key member of the RGS family of oncogenes that contribute to the malignant progression of a number of human cancer types, but this remains to be further investigated (Xie et al., 2016).
Characteristics and functions of RGS16
Orientation and structure
The RGS16 protein belongs to the B/R4 subfamily of RGS proteins, which are highly conserved in mammals. In humans and mice, most of the genes encoding B/R4 subfamily proteins are located on chromosome 1, except for RGS3, which is located on chromosome 9, and composed of two or more clusters of genes, such as RGS4 and RGS5 on 1q23.3, RGS8 and RGS16 on 1q25.3, and RGS1, 2, 13, 18 and RGS21 on 1q31.2 (Sierra et al., 2002) (Figure 3). Furthermore, the RGS1/RGS16 neighboring region constitutes a synteny group that is highly conserved in tetrapods, and genes in this region are closely homologous to major histocompatibility complex (MHC) or other MHC paralogs on chromosome 6, providing a useful marker for studying the origin and evolution of MHC (Suurväli et al., 2013).
FIGURE 3
RGS16 was originally cloned from the retina by Snow BE et al. At the same time, they revealed that RGS16 is highly expressed in the retina and is also involved in the visual signaling pathway (; Snow et al., 1998a; ). With the exception of the RGS3 protein, other members of the B/R4 subfamily, including RGS16, also contain short, disordered amino- and carboxy-terminal extensions and an α-helix based on a conserved and functional RGS domain (). RGS16 contains a core RGS structural domain, located between amino acids 62 and 180. This structural domain is highly conserved between yeast and mammalian RGS proteins (). Human RGS16 is most similar to RGS3 (175 amino acids at the C-terminus, GenBank U27655), and mouse RGS16 (U72881) shares 86% identity with human (; Snow et al., 1998a). (Figure 4)A very short unique membrane binding domain with amphiphilic characteristics at the NH2 terminus of RGS16 provides the structural basis for its membrane binding and biological activity (). The core RGS domain of RGS16 maintains full G-protein binding and GTP-activating protein activity in vitro, but its NH2-terminal domain is also required for in vivo membrane binding and bioactivity, as evidenced by its ability to attenuate pheromone signaling in yeast (). Membrane interacting protein of RGS16 (miR16), a putative membrane glycerol phosphodiester phosphodiesterase, is required for its interaction with the RGS structural domain of RGS16, and analysis of deletion mutants suggests that the N-terminal region of the RGS domain in RGS16 is required for its interaction with miR16 (Zheng et al., 2000). Novel interactions between RGS proteins (RGS4, RGS5and RGS16) and the multifunctional protein 14-3-3 have been identified, and their interactions do not depend on any post-translational modifications, with the 14-3-3 protein acting as a molecular chelator that selectively blocks RGS proteins from interacting with Gα and ultimately prolongs or enhances specific G protein-mediated signaling (). A comprehensive understanding of the structure of the RGS16 protein and its interaction is crucial, and the crystal structure of Gα in complex with RGS16 in the GTP hydrolysis transition state is shown in Figure 5 (Slep et al., 2008; Soundararajan et al., 2008).
FIGURE 4
FIGURE 5
Regulation of RGS16 expression and function
RGS16is also known as A28-RGS14 or RGS-rand is expressed in a variety of tissues and cells, being expressed at high levels in the retina, pituitary gland, bone marrow and liver (; ; Snow et al., 1998a). It has emerged as an important regulator of cellular processes under different pathological and physiological conditions. Examples of RGS16 protein, that function as GAPs at the cellular level is regulation of the intensity and duration of the entire G protein signaling process, thereby terminating the G protein signaling pathway, are as follows: RGS16 interacts with protease-activated receptor 2 (PAR2) in the presence of Gαi to inhibit PAR2/Gαi-mediated signal transduction (). RGS16 binds to the β2 adrenergic receptor and suppressed GαS mediated signal transduction. The role of RGS16 in regulating the response of osteoblastic ovarian cancer G protein-coupled receptor 1 to metabolic acidity stimulates osteoclast bone resorption capacity, as GAPs affect downstream signaling, which contributes to the understanding of bone loss in patients with chronic nephropathy acidosis (). In summary, RGS16 protein acts through the classical GPCR pathway, while subsequent studies have illustrated that RGS16 protein also influences disease processes through non-classical pathways, including the MAPK, PI3K/Akt, Rho AandSDF-1/CXCR4 pathways (; ; ). Liang et al. revealed that RGS16 protein expression is upregulated in breast cancer cells and inhibits the activation of the PI3K signaling pathway via epidermal growth factor receptor (EGFR), thereby suppressing the proliferation of breast cancer cells ().
Studies have demonstrated that the activity and function of RGS16 protein can be affected by post-translational modifications, including phosphorylation and palmitoylation (; ; ; ). Data have indicated that the RGS16 protein contains two conserved tyrosine residues, Tyr168 and Tyr177, in the RGS box, which are predicted phosphorylation sites bi-directionally regulating the GAP activity of RGS16 (). EGFR-mediated tyrosine phosphorylation of the RGS16 protein at the Tyr168 residue reduces its GAP function on the Gα subunit, thereby impairing its inhibition of ligand-stimulated MAPK activity. Mutation of the Tyr177 residue of RGS16 does not affect its GAP activity in vitro, but eliminates the ability of RGS16 to regulate Gq-coupled MAP kinase activation or Gi-mediated inhibition of adenylate cyclase (). Instead of affecting the intracellular localization or GAP activity of RGS16, Alexandrine Derrien et al. verified that tyrosine kinase-mediated phosphorylation of RGS16 did not affect its intracellular localization, but promoted its stability (). Additionally, RGS16 is constitutively phosphorylated at the serine 194 site when expressed in HEK293T cells, whereas in cells expressing the α2A adrenergic receptor, serine 53 is phosphorylated in a ligand-dependent manner in response to adrenergic stimulation. Phosphorylation of these two sites impairs their GAP activity and subsequently attenuates heterotrimeric G protein-stimulated extracellular signal-regulated protein kinase activity (). S-palmitoylation, or S-acylation, refers to the covalent modification of long-chain fatty acids (usually 16-carbon palmitic acid) to protein cysteine residues via thioester bonds, which occurs on several molecules of the G-protein linkage signaling pathway, and is a dynamic and reversible form of post-translational modification that is widely present in living organisms and serves an important role in regulating protein transport, cellular localization and stability, and is involved in a number of biological processes and closely related to the occurrence and development of numerous diseases (). In a previous study, RGS16 was involved in the membrane localization at the NH2-terminal palmitoylation sites Cys-2 and Cys-12 of the RGS box (; ). Furthermore, Chen C et al. reported palmitoylation of RGS16 in Saccharomyces cerevisiae, but this modification does not require plasma membrane binding or adapter signaling regulation (; ). Overall, there may be differences in palmitoylation of RGS16 among different species; however, this usually has an effect on the activity of RGS16.
Role of RGS16 in tumors
RGS proteins and GPCR-mediated signaling pathways often serve a key role in tumorigenesis, and certain hallmark oncogenic processes, such as uncontrolled growth, invasion, and metastasis, can be attributed to alterations in GPCR signaling pathways. Therefore, as a member of the RGS protein family and an important regulatory protein of the GPCR pathway, RGS16 undoubtedly serves a nonnegligible role in tumorigenesis. More specifically, recent studies have found that the RGS16 protein is associated with a variety of cancer types, including breast cancer (Wiechec et al., 2008; ; Wiechec et al., 2011; ), pancreatic cancer (; ; Ocal et al., 2015; Zolghadri et al., 2018; ), colorectal cancer (; ), neuroblastoma (; ), glioma (), chondrosarcoma (Sun et al., 2015), hyper diploid acute lymphoblastic leukemia in children () and other malignant tumors. RGS16 has been studied in breast cancer. Allelic imbalance mapping analysis verified that the 1q25.3 region where the RGS16 protein is located is highly unstable in breast tumors, and RGS16 expression was reduced in breast cancer samples due to allelic imbalance, intragenic chromosomal break points and methylation (Wiechec et al., 2008). Additionally, δEF1 family proteins (δEF1/zinc finger E-box binding homeobox 1 and Smad interacting protein-1/zinc finger E-box binding homeobox 2), key regulators of epithelial-mesenchymal transition (EMT), inhibit RGS16 expression and promotebreast cancer cell invasion, suggesting that low RGS16 expression may contribute to the promotion of cancer cell motility by δEF1 family proteins (). On the contrary, high RGS16 expression in breast tumors attenuates the growth factor-induced PI3K signaling pathway, thereby inhibiting proliferation, human epidermal growth factor receptor 2 activation and resistance to chemotherapeutic agents in breast tumor cells (). Overall, these discoveries indicate that RGS16 has a critical effect in breast cancer progression through allelic analysis, δEF1 family protein inhibition and GPCR-independent pathways, demonstrating that RGS16 may be a novel therapeutic target in breast cancer.
In parallel to the investigation of RGS16 in breast cancer, several relevant studies have also linked changes in RGS16 expression to poor prognosis of cancer. For example, in patients with pancreatic cancer with lymph node metastasis, the RGS16 and FosB expression is markedly reduced in pancreatic cancer andis closely associated with a decreased survival rate of patients (). Expression of RGS16- green fluorescent protein (GFP), which inhibits Gi/q-coupled GPCRs, negatively regulates pancreatic ductal adenocarcinoma (PDA) progression and can be used for rapid preclinical in vivo validation of novel chemotherapeutic agents targeting early lesions in patients at high risk for successful resection or progression to PDA. RGS16-GFP has recently been reported in caerulein-induced acinar cell dedifferentiation, early tumor and throughout PDA progression () (Ocal et al., 2015). This suggests that RGS16 may be used as a prognostic marker for pancreatic cancer and PDA. Additionally, a recent study has suggested that RGS16 can be used as a diagnostic biomarker for immune subtypes of ovarian cancer and as a biomarker to predict the clinical stage of the disease ().
In colorectal cancer, however, RGS16has a completely different biological function. RGS16 mRNA and protein expression in colorectal cancer tissues is higher than that in normal tissues, but the prognosis of patients with high RGS16 expression is worse than that of patients with low RGS16 expression, and RGS16 can be used as a prognostic indicator for patients with colorectal cancer (). Other recent in vitro experiments have revealed that RGS16 is oversaturated in glioma cell lines and facilitates tumor cell proliferation and migration through the EMT process, suggesting the potential of RGS16 as a novel prognostic biomarker and therapeutic target (). Therefore, such studies imply that RGS16 may serve as a biomarker for diagnosis and prognosis in cancer. Many studies (summarized in Table 1) have shown that RGS16 expression is regulated by various stimuli in different cell types and disease models.
TABLE 1
| Samples sources | Stimuli/Disease model | mRNA/Protein | Expression | Year | References |
|---|---|---|---|---|---|
| Primary bone cell | Chronic metabolic acidosis (MET) | mRNA/Protein | Decrease | 2021 | |
| Tumor and blood DNA samples | Primary sporadic breast cancer | mRNA/Protein | Decrease | 2008 | Wiechec et al. (2008) |
| Breast cancer cells | dEF1 family proteins | mRNA/Protein | Decrease | 2015 | |
| Breast cancer cell line MCF7 | EGF/PI3K | mRNA/Protein | Decrease | 2009 | |
| Pancreatic cancer tissue specimens | Pancreatic cancer with lymph node metastasis | mRNA/Protein | Decrease | 2010 | |
| KIC; RGS16::GFP mice | Pancreatic ductal adenocarcinoma (PDA) | mRNA | Increase | 2020 | |
| KIC; RGS16::GFP mice | Pancreatic ductal adenocarcinoma (PDA) | mRNA | Increase | 2015 | Ocal et al. (2015) |
| Twenty-two cell lines derived from human gastrointestinal cancer | Gastrointestinal cancer | mRNA/Protein | Increase | 2009 | |
| Human neuroblastoma BE (2)-C and SH-SY5Y cell lines | Retinoic acid-induced neuroblastoma cells | Protein | Decrease | 2005 | |
| The CGGA microarray database | Glioma | mRNA | Increase | 2020 | |
| Primary Human Chondrosarcoma Tissue; Chondrosarcoma cell line JJ | MIR-181a/Chondrosarcoma | mRNA/Protein | Decrease | 2015 | Sun et al. (2015) |
| The array CGH study | Hyper diploid acute lymphoblastic leukemia | mRNA | Increase | 2007 | |
| The UCSC Xena database | Ovarian cancer | mRNA | Increase | 2021 | |
| THP1 | LPS(1 ug/ml) Pam3CysSK4(10 ng/ml)2, 4, 6, 8 and24 h | mRNA | Increase | 2015 | Suurväli et al. (2015) |
| DC | LPS (10 ng/ml) IL-10 (50 ng/ml)2 and 8 h | mRNA | Increase | 2004 | Shi et al. (2004) |
| PBCs; U937 and the 293 human embryonic kidney cell lines | IL-2 (500 Pm) | mRNA/Protein | Increase | 1999 | |
| RGS16−/− mice; Th1, Th2, or Th17 | Pulmonary inflammation | mRNA/Protein | Increase | 2012 | Shankar et al. (2012) |
| RGS16 Tg mice | Allergic inflammation | mRNA | Increase | 2003 | |
| B cell; 70Z/3 cell line | IL-17 (30 ng/ml) 5,15,30,60 min | mRNA/Protein | Increase | 2010 | Xie et al. (2010) |
| CD4+Tcell | IL-17 (30 ng/ml) 1, 4 and 24 h | mRNA/Protein | Increase | 2013 | |
| CD8+ splenic T cells from the RGS16mCherry-Cre-ERT2 | Promotes antitumor CD8+ T cell exhaustion | mRNA/Protein | Increase | 2022 | Weisshaar et al. (2022) |
| Porcine kidney cell line PK-14/A | LPS(2.5 ug/ml) PHA (1 ug/ml) ConA(5 ug/ml) polyI:C (5 ug/ml) | mRNA | Increase | 2009 | Timmusk et al. (2009) |
| Porcine kidney cell line PK-15/A | Porcine circovirus type 2 (PCV2) | Protein | Decrease | 2015 | |
| C57BL/6 mice | During fasting | mRNA/Protein | Increase | 2006 | |
| INS-1-derived 832/13 rat insulinoma cells | Carbohydrate response element binding protein (ChREBP) | mRNA | Increase | 2016 | Sae-Lee et al. (2016) |
| AML12 cells; AAV8-Arg2 db/db mice | Non-alcoholic fatty liver disease | mRNA/Protein | Decrease | 2019 | Zhang et al. (2019) |
| Primary hepatocyte; HEK293A; Hepa1-6; C57BL/6J | Bioactive lipid accumulation, and hepatic inflammation | mRNA/Protein | Decrease | 2021 | |
| RGS16::GFP mice | Embryonic endocrine pancreas and mouse models of diabetes | Protein | Increase | 2010 | Villasenor et al. (2010) |
| Male Wistar rats and C57BL/6N mice | 6-month-old Wistar rats infused with glucose or saline for 72 h; Isolated rat islets exposed to 2.8 or16.7 mM glucose for 24 h | mRNA | Increase | 2016 | Vivot et al. (2016) |
| MO7e cells | During megakaryocyte differentiation | mRNA | Increase | 2006 |
Pathophysiological roles of RGS16.
In terms of malignancies, synergistic expression of dual specificity phosphatase 6 and RGS16 blocks the growth of retinoic acid-induced neuroblastoma cells (). A novel mechanism by which microRNA-181a increases CXCR4 signaling through inhibition of RGS16 protein promotes chondrosarcoma growth, angiogenesis, and metastasis (Sun et al., 2015). Finally, RGS16 protein is aberrantly expressed in hyper diploid acute lymphoblastic leukemia, suggesting that RGS16 may be involved in hematologic malignancies (). Above all, RGS16 protein exerts a critically influential regulatory effect in these malignancies through GPCRs and other non-classical signaling pathways, and has the to be a potential therapeutic target for the regulation of tumor processes.
RGS16 in immunity and inflammation
Immune cells are involved in the development of numerous diseases, and a number of key regulatory molecules can participate in the progression of related diseases by affecting the function of these immune cells. Similar to our and other teams’ previous studies, hepatitis B e antigen (HBeAg) induces activation of macrophages via the TLR-2/nuclear factor-κB (NF-κB) signaling pathway, further aggravating liver fibrosis (Xie et al., 2021) and the ERK/cyclic adenosine monophosphate (cAMP)-response element binding protein/microRNA-212–3p negative feedback loop to inhibit HBeAg-induced macrophage activation, and thus, aggravates liver injury (). As one of the newly discovered molecules, accumulating data have indicated that RGS16 is expressed in various immune cells such as monocytes (Suurväli et al., 2015), T lymphocytes (), dendritic cells (Shi et al., 2004) and natural killer cells (). Therefore, this section mainly summarizes the expression of RGS16 in a variety of immune cells and its known functions in inflammation.
RGS16 is a crucial modulator of inflammatory responses and can inhibit pro-inflammatory responses (Shankar et al., 2012). Suurväli J reported that overexpression of RGS16 inTHP-1 cells was associated with decreased production of the pro-inflammatory cytokines interleukin (IL)-1β, IL-6 and TNFα after lipopolysaccharide (LPS) stimulation, while RNAi knockdown of RGS16 in THP-1 cells was associated with increased expression of the pro-inflammatory cytokines IL-1β, IL-6 and TNFα after LPS stimulation (Suurväli et al., 2015). Furthermore, the RGS16 gene was up-regulated 100 times in human monocyte-derived dendritic cells treated with LPS compared with untreated cells (Perrier et al., 2004). One of the mechanisms by which TLRs, important pattern recognition receptors on dendritic cells, alter GPCR signaling is by altering RGS expression, and it has been demonstrated that TLR3 or TLR4 is involved in the induction of RGS16 expression on monocyte-derived dendritic cells in human and mice, although more so in human cells than in mouse cells (Shi et al., 2004). Therefore, RGS16 expression was markedly increased on monocytes and monocyte-derived dendritic cells after LPS treatment, implying that RGS16 may be engaged in innate immune-related inflammatory diseases.
In addition, RGS16 expression is markedly altered in B and T cells when they are exposed to different conditions, suggesting that RGS16 also serves an essential role in adaptive immunity (). It has been demonstrated that RGS16 expression is upregulated in human primary T lymphocytes after IL-2 stimulation; however, excessive cAMP inhibits RGS16 expression on T cells (). Allergic respiratory inflammation often accompanies human asthma and produces inflammatory responses such as allergy cytokine (IL-3, IL-4, IL-5) production, airway eosinophil recruitment, presence of immunoglobulin E (atopic) and increased mucus secretion from cupped cells. However, the accumulation of these inflammatory changes can lead to airway sensitivity to narrowing triggers, causing allergic airway inflammation which has been reported to be associated with RGS16 (). Chemokine-induced recruitment of T lymphocytes to the lung is essential for allergic inflammation, and RGS16 has been demonstrated to affect T cell migration and activation by restricting the signaling pathways of chemokine receptors CXCR4, C-C motif chemokine receptor 3 and C-C motif chemokine receptor 5, thereby affecting allergic inflammation (; Shankar et al., 2012). In earlier studies, RGS16 transgenic mice in an allergic airway model had reduced numbers of lung T helper 2 (Th2) cells and markedly increased numbers of Th2 cells produced by lymphoid-like organs, leading to severe generalized inflammation and airway hyperresponsiveness (AHR) disease (). There are also reports that RGS16 suppresses pulmonary inflammation by regulating chemokines, such as C-C motif chemokine receptor 4, C-C motif chemokine receptor 10, and C-C motif chemokine ligand 17, which mediate T-cell restriction of Schistosoma mansoni granulomas (Shankar et al., 2012). RGS16 protein has also been reported to attenuate the lung T helper 17 cell inflammatory response (Shankar et al., 2012). Recent literature indicates that RGS16 synergizes with programmed cell death protein 1 blockade and promotes antitumor cluster of differentiation 8-positive T cell failure in an ERK1-dependent manner (Weisshaar et al., 2022). Similar to T cells, the function of B cells, one of the important adaptive immune cells, is also regulated by RGS16. The germinal center (GC) is a structure located within the secondary lymphoid follicles and is the site of proliferation, selection, maturation and death of B cells (). Spontaneous GC formation exists in mouse models of autoimmune disease, and human autoimmune disease may be associated with GC formation or dysfunction (; ). Specific cellular foci that promote the interactions of antigen presentation and T and/or B cells during normal immune responses are referred to as spontaneous GCs. These are formed in the presence of C-X-C motif chemokine ligand 12(CXCL12) and C-X-C motif chemokine ligand 13, while RGS proteins downregulate lymphocyte responses to these chemokines, thereby retarding B and T cell migration (Walker et al., 2003). It has been reported that RGS16 is mainly expressed in cluster of differentiation 4-positive (CD4+) T cells and B cells of GCs, which can accelerate the intrinsic rate of the Gα GTPase reaction and down-regulate the response of lymphocytes to chemokines, thus delaying the migration of CD4+ T cells and B cells of GCs () (). For example, IL-17 targets self-reactive B cells in BXD2 mice, rapidly activates the NF-κB signaling pathway, leads to upregulation of RGS16 expression in spontaneous development centers, delays B cell migration, and promotes the formation of spontaneous GCs (Xie et al., 2010) (). These data all suggest that RGS16 serves an important role in the migration of T and B cells.
RGS16 is utilized not only by organisms to regulate the function of various immune cells, but also by pathogens to disrupt the host immune response and promote inflammatory responses. Sequence analysis of the non-structural protein encoded by porcine circovirus type 2 (PCV2) open reading frame 3 (ORF3) indicates that it is closely related to human and murine RGS16. Immunofluorescent labeling has confirmed the induced expression of poRGS16 at the protein level and revealed that PCV2 ORF3 protein co-localizes with poRGS16 in LPS-activated porcine peripheral blood mononuclear cells (Timmusk et al., 2009). Additionally, the PCV2 ORF3 protein promotes the degradation of RGS16, further enhances the nuclear translocation of NF-κB through the ERK1/2 signaling pathway, and promotes the secretion of IL-6 and IL-8 from porcine epithelial cells, which is the reason why a severe inflammatory response and leukocyte infiltration will be induced around the host cells early in PCV2 infection (). This is a good example of how pathogens can utilize the RGS16 protein to disrupt the host immune response and promote inflammation. Recently Seung-Hoon Lee et al. detected single nucleotide polymorphisms (SNPs) in the RGS16 region, which were associated with PCV2 viral load in 22 identified SNPs and in both haplotype and double haplotype analyses, and in conclusion, they demonstrated that RGS16 SNPs affect PCV2 viral load ().
RGS16 in biorhythms and metabolism
As one of the candidate biological clock/bio-clock control genes, RGS16 is mainly expressed in the suprachiasmatic nucleus (SCN) and thalamus of the brain and in the liver, suggesting that RGS16 is associated with central and peripheral circadian clocks (; Ueda et al., 2002; ). The SCN is the main circadian pacemaker in mammals and is a network structure consisting of multiple types of neurons. A key feature of RGS16 is that it functions in the SCN in a time-specific manner (). G protein-coupled receptor 176 (Gpr176) is an orphan SCN-rich GPCR that determines the speed of the central clock of the SCN (). Naoto Hayasaka et al. demonstrated that RGS16 is involved in two independent but interacting circadian rhythm systems, light-entrainable oscillator and food-entrainable oscillator. Compared with wild-type mice, RGS16 knockout mice exhibited shorter rhythms of locomotor activity and reduced total activity. In addition, SCN-controlled food anticipatory activity was diminished when feeding was restricted during the day in these knockout mice, suggesting that RGS16 is closely associated with Gpr176 and regulates central biological rhythmic processes via the GPCR pathway ().
In terms of the peripheral biological clock, Huang J reported that RGS16 is predominantly expressed in periportal hepatocytes during the last hours of the daily fast, which are predominantly lipolytic and gluconeogenic (). Interestingly, it has been previously demonstrated that RGS16 mRNA and protein are upregulated during fasting and rapidly downregulated upon resumption of fasting (). Compared with wild-type mice, RGS16 knockout mice developed fatty liver after 10 days of a high-fat, high-carbohydrate diet and exhibited higher fatty acid oxidation rates and plasma β-ketone levels, in contrast to transgenic mice expressing RGS16 protein specifically in the liver, which exhibited the opposite phenotype and low glucose levels and developed fatty liver after overnight fasting. The glucose-dependent transcription factor carbohydrate response element-binding protein (ChREBP) induces fatty acid synthesis, which in turn is required to induce RGS16 expression during fasting, suggesting that RGS16 feedback inhibits fatty acid oxidation in the liver (Sae-Lee et al., 2016). Furthermore, Zhang Y et al. revealed that arginase 2 (Arg2) was a fasting-induced hepatocyte factor and was upregulated under fasting conditions and after treatment with alginate, an inhibitor of ChREBP, to prevent liver and peripheral fat accumulation, liver inflammatory response, insulin, and poor glucose tolerance in an obese mouse model. Interestingly, Arg2 can inhibit RGS16 expression and RGS16 gene recombination can reverse the effects of Arg2 overexpression, suggesting that Arg2 reduces hepatic fat accumulation in hepatocytes by inhibiting RGS16 (Zhang et al., 2019). Circadian-induced expression of G0/G1 switch 2 and RGS16 in hepatocytes, which regulates substrate oxidation in resting hepatocytes, has recently been reported to reduce liver inflammation and fibrosis in obese mice, suggesting that RGS16 is essential for maintaining liver health (). Therefore, RGS16 expression in hepatocytes is controlled by feeding and fasting and can inhibit fatty acid metabolism through ChREBP and promote lipid synthesis under the control of Arg2. Apart from being influenced by biorhythms in the liver, RGS16 has also been reported to be influenced by biorhythms in the pancreas. Mice with deletion of the RGS16 gene develop a dedifferentiated exocrine pancratia at 2 months of age and become malnourished, underweight, hypoglycemicand hypothermic (Zolghadri et al., 2018). RGS16 and RGS8 are expressed in embryonic pancreatic progenitor and endocrine cells and disappear in adults; however they are reactivated in type I and II diabetes models, which suggests that the RGS16 and RGS8 proteins may become a novel target for further treatment of diabetes (Villasenor et al., 2010). In rodent and human islets, RGS16 is a novel regulator of β-cell function that promotes insulin secretion and β-cell proliferation by limiting the tonic inhibitory signal exerted on islets through δ-cell-derived somatostatin (Vivot et al., 2016). Overall, RGS16 may be an active therapeutic strategy for the treatment of fat accumulation, liver inflammatory diseases, and insulin and glucose intolerance mediated by biorhythms.
Effect of RGS16 in coagulation
Platelets have no nucleus and are cytoplasmic fragments derived from bone marrow megakaryocytes (Rendu and Brohard-Bohn, 2001). Their principal function is to promote hemostasis and accelerate clotting by responding, together with clotting factors, to bleeding from vascular injury (Ross et al., 1988). Additionally, RGS16 protein is highly expressed in megakaryocytes and platelets (; ). It has recently been proposed that RGS16 moderate’s platelet function and thus influences the coagulation process (Zhang et al., 1999; ; ; ). Previously, it has been observed that overexpression of RGS16 in the megakaryocyte MO7e cell line inhibitsSDF-1-induced migration and leads to MAPK and AKT inactivation, thereby affecting platelet coagulation (). The platelet-secreted chemokine CXCL12 activates platelets in an autocrine/paracrine manner (Walsh et al., 2015). Compared with wild-type mice, platelets in a RGS16 knockout mouse model exhibited increased protease-activated receptor 4 and collagen-induced aggregation, as well as markedly increased agonist-dependent platelet aggregation, dense granule and alpha granule release, integrin αIIbβ3 activation, and phosphatidylserine exposure after CXCL12 stimulation. In addition, ERK and Akt phosphorylation levels in platelets were also considerably enhanced after CXCL12 stimulation. These phenomena suggest that RGS16 serves an important role in the coagulation process by regulating platelet activation through CXCL12 (). Similarly, the RGS16 protein attenuates the stimulation of MAPK p38 by G protein-coupled platelet-activated factor PAF receptor, potentially affecting the function of the PAF receptor in coagulation (Zhang et al., 1999). Based on the above, RGS16 protein may also affect platelet function through some non-classical pathways, which is not well studied, but may be a potential mechanism for the treatment of coagulation disorders.
Conclusion and prospects
Since its discovery at the end of the 20th century, there has been tremendous progress in understanding the structure, function and regulatory mechanisms of RGS16, as well as its potential role in various pathophysiological states. Despite its simple structure, the studies discussed in the present review suggest that RGS16 is an important regulator in immune, inflammatory, tumor, biological rhythm and metabolic disorders, and coagulation dysfunction. It has been demonstrated that the function of RGS16 can be affected at the transcription and post-translation levels, including by induced expression, and modification through phosphorylation and palmitoylation, although this has not been well established and has mostly been reported in cell models, with a lack of studies on specific cells or disease models. RGS16 is expressed in a variety of immune cells and affects the function of these immune cells involved in the development of immune and inflammatory diseases, and this aspect has not been studied in detail. In addition, RGS16 serves a non-negligible role in tumorigenesis, especially in the progression of breast cancer, for which it may be a novel therapeutic target, and its expression levels are also a biomarker for the diagnosis and prognosis of pancreatic cancer, PDA, colorectal cancer and glioma; however, its expression has only been tested in relation to prognosis. In addition, RGS16 is a candidate biomarker for the regulation of central and peripheral biorhythms, and its role has been confirmed in knockout mice; however, the specific mechanism is not clear. Furthermore, it also affects platelet function, and thus, the development of coagulation through non-classical signaling pathways. Finally, although RGS16 is involved in the regulation of classical and other non-classical signaling pathways, its specific interacting molecules and phosphorylation or palmitoylation modification status in these signaling pathways remain to be studied. In conclusion, RGS16 serves an important regulatory role in the development and process of various diseases via GPCRs and other non-classical signaling pathways. Although this has not yet been examined in-depth, it may suggest potential mechanisms and targets for the treatment of these diseases.
Statements
Author contributions
Conception and design: JQ and XT. Collection and assembly of data: MT, YM, TL, NW. Data analysis and interpretation: MT, JL, HJ, MY, WW. Manuscript writing: MT, HB, XT, JQ. Administrative support: WW and JQ. Final approval of manuscript: All authors.
Funding
This work was supported in part by grants from the National Natural Science Foundation of China (81600469), the Clinical Medical Science and Technology Innovation Program (202019094), the Natural Science Foundation of Shandong Province (ZR2020QH035) and WBE Liver Fibrosis Foundation (CFHPC2021011).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Glossary
- GPCRs
G protein-coupled receptors
- GDP
Guanosine diphosphate
- GEFs
Guanine-nucleotide exchange factors
- GTP
Guanosine triphosphate
- RGS
Regulators of G protein signaling
- GTPase
guanosine triphosphatase
- MAPK
mitogen-activated protein kinase
- PI3K
phosphoinositide 3-kinase
- AKT
protein kinase B
- Rho A
Ras homolog family member A
- SDF-1
stromal cell-derived factor 1
- CXCR4
C-X-C motif chemokine receptor 4 pathways
- GAPs
GTPase activating proteins
- ERK
extracellular regulated protein kinases
- TNFα
tumor necrosis factor α
- TLR
toll-like receptor
- MHC
major histocompatibility complex
- PAR2
protease-activated receptor 2
- HER2
human epidermal growth factor receptor-2
- EGFR
epidermal growth factor receptor
- EMT
epithelial-mesenchymal transition
- GFP
green fluorescent protein
- PDA
pancreatic ductal adenocarcinoma
- HBeAg
hepatitis B e antigen
- NF-κB
nuclear factor-κB
- cAMP
cyclic adenosine monophosphate
- IL
interleukin
- LPS
lipopolysaccharide
- AHR
airway hyperresponsiveness
- GC
germinal center
- CXCL12
C-X-C motif chemokine ligand 12
- CD4+
cluster of differentiation 4-positive
- PCV2
porcine circovirus type 2
- ORF3
open reading frame 3
- SNPs
single nucleotide polymorphisms
- SCN
suprachiasmatic nucleus
- Gpr176
G protein-coupled receptor 176
- ChREBP
carbohydrate response element binding protein
- Arg2
arginase 2
References
1
Abramow-NewerlyM.MingH.ChidiacP. (2006). Modulation of subfamily B/R4 RGS protein function by 14-3-3 proteins. Cell. Signal.18 (12), 2209–2222. 10.1016/j.cellsig.2006.05.011
2
AiroldiI.RaffaghelloL.PiovanE.CoccoC.CarliniB.AmadoriA.et al (2006). CXCL12 does not attract CXCR4+ human metastatic neuroblastoma cells: Clinical implications. Clin. Cancer Res.12 (1), 77–82. 10.1158/1078-0432.CCR-05-1376
3
AlmutairiF.LeeJ. K.RadaB. (2020). Regulator of G protein signaling 10: Structure, expression and functions in cellular physiology and diseases. Cell. Signal.75, 109765. 10.1016/j.cellsig.2020.109765
4
AlqinyahM.AlmutairiF.WendimuM. Y.HooksS. B. (2018). RGS10 regulates the expression of cyclooxygenase-2 and tumor necrosis factor Alpha through a G protein-independent mechanism. Mol. Pharmacol.94 (4), 1103–1113. 10.1124/mol.118.111674
5
AlqinyahM.HooksS. B. (2018). Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins. Cell. Signal.42, 77–87. 10.1016/j.cellsig.2017.10.007
6
BaiX.LiaoY.SunF.XiaoX.FuS. (2021). Diurnal regulation of oxidative phosphorylation restricts hepatocyte proliferation and inflammation. Cell. Rep.36 (10), 109659. 10.1016/j.celrep.2021.109659
7
BansalG.DrueyK. M.XieZ. (2007). R4 RGS proteins: Regulation of G-protein signaling and beyond. Pharmacol. Ther.116 (3), 473–495. 10.1016/j.pharmthera.2007.09.005
8
BeadlingC.DrueyK. M.RichterG.KehrlJ. H.SmithK. A. (1999). Regulators of G protein signaling exhibit distinct patterns of gene expression and target G protein specificity in human lymphocytes. J. Immunol.162 (5), 2677–2682.
9
BermanD. M.KozasaT.GilmanA. G. (1996). The GTPase-activating protein RGS4 stabilizes the transition state for nucleotide hydrolysis. J. Biol. Chem.271 (44), 27209–27212. 10.1074/jbc.271.44.27209
10
BerthebaudM.RiviereC.JarrierP.FoudiA.ZhangY.CompagnoD.et al (2005). RGS16 is a negative regulator of SDF-1-CXCR4 signaling in megakaryocytes. Blood106 (9), 2962–2968. 10.1182/blood-2005-02-0526
11
BuckbinderL.Velasco-MiguelS.ChenY.XuN.TalbottR.GelbertL.et al (1997). The p53 tumor suppressor targets a novel regulator of G protein signaling. Proc. Natl. Acad. Sci. U. S. A.94 (15), 7868–7872. 10.1073/pnas.94.15.7868
12
CarperM. B.DenvirJ.BoskovicG.PrimeranoD. A.ClaudioP. P. (2014). RGS16, a novel p53 and pRb cross-talk candidate inhibits migration and invasion of pancreatic cancer cells. Genes. Cancer5 (11-12), 420–435. 10.18632/genesandcancer.43
13
ChanR. K.OtteC. A. (1982). Isolation and genetic analysis of Saccharomyces cerevisiae mutants supersensitive to G1 arrest by a factor and alpha factor pheromones. Mol. Cell. Biol.2 (1), 11–20. 10.1128/mcb.2.1.11-20.1982
14
ChenC. K.WielandT.SimonM. I.Rgs-r (1996). RGS-r, a retinal specific RGS protein, binds an intermediate conformation of transducin and enhances recycling. Proc. Natl. Acad. Sci. U. S. A.93 (23), 12885–12889. 10.1073/pnas.93.23.12885
15
ChenC.LinS. C. (1998). The core domain of RGS16 retains G-protein binding and GAP activity in vitro, but is not functional in vivo. FEBS Lett.422 (3), 359–362. 10.1016/s0014-5793(98)00042-8
16
ChenC.SeowK. T.GuoK.YawL. P.LinS. C. (1999). The membrane association domain of RGS16 contains unique amphipathic features that are conserved in RGS4 and RGS5. J. Biol. Chem.274 (28), 19799–19806. 10.1074/jbc.274.28.19799
17
ChenC.WangH.FongC. W.LinS. C. (2001). Multiple phosphorylation sites in RGS16 differentially modulate its GAP activity. FEBS Lett.504 (1-2), 16–22. 10.1016/s0014-5793(01)02757-0
18
ChenC.ZhengB.HanJ.LinS. C. (1997). Characterization of a novel mammalian RGS protein that binds to Galpha proteins and inhibits pheromone signaling in yeast. J. Biol. Chem.272 (13), 8679–8685. 10.1074/jbc.272.13.8679
19
ChenW.BianH.XieX.YangX.BiB.LiC.et al (2020). Negative feedback loop of ERK/CREB/miR-212-3p inhibits HBeAg-induced macrophage activation. J. Cell. Mol. Med.24 (18), 10935–10945. 10.1111/jcmm.15723
20
ChoiC. Y.RhoS. B.KimH. S.HanJ.BaeJ.LeeS. J.et al (2015). The ORF3 protein of porcine circovirus type 2 promotes secretion of IL-6 and IL-8 in porcine epithelial cells by facilitating proteasomal degradation of regulator of G protein signalling 16 through physical interaction. J. Gen. Virol.96 (5), 1098–1108. 10.1099/vir.0.000046
21
CraftJ. E. (2012). Follicular helper T cells in immunity and systemic autoimmunity. Nat. Rev. Rheumatol.8 (6), 337–347. 10.1038/nrrheum.2012.58
22
CunninghamM. L.WaldoG. L.HollingerS.HeplerJ. R.HardenT. K. (2001). Protein kinase C phosphorylates RGS2 and modulates its capacity for negative regulation of Galpha 11 signaling. J. Biol. Chem.276 (8), 5438–5444. 10.1074/jbc.M007699200
23
DavidssonJ.AnderssonA.PaulssonK.HeidenbladM.IsakssonM.BorgA.et al (2007). Tiling resolution array comparative genomic hybridization, expression and methylation analyses of dup(1q) in Burkitt lymphomas and pediatric high hyperdiploid acute lymphoblastic leukemias reveal clustered near-centromeric breakpoints and overexpression of genes in 1q22-32.3. Hum. Mol. Genet.16 (18), 2215–2225. 10.1093/hmg/ddm173
24
De VriesL.ElenkoE.HublerL.JonesT. L.FarquharM. G. (1996). GAIP is membrane-anchored by palmitoylation and interacts with the activated (GTP-bound) form of G alpha i subunits. Proc. Natl. Acad. Sci. U. S. A.93 (26), 15203–15208. 10.1073/pnas.93.26.15203
25
De VriesL.Gist FarquharM. (1999). RGS proteins: More than just GAPs for heterotrimeric G proteins. Trends Cell. Biol.9 (4), 138–144. 10.1016/s0962-8924(99)01515-9
26
DerrienA.DrueyK. M. (2001). RGS16 function is regulated by epidermal growth factor receptor-mediated tyrosine phosphorylation. J. Biol. Chem.276 (51), 48532–48538. 10.1074/jbc.M108862200
27
DerrienA.ZhengB.OsterhoutJ. L.MaY. C.MilliganG.FarquharM. G.et al (2003). Src-mediated RGS16 tyrosine phosphorylation promotes RGS16 stability. J. Biol. Chem.278 (18), 16107–16116. 10.1074/jbc.M210371200
28
DingY.LiJ.WuQ.YangP.LuoB.XieS.et al (2013). IL-17RA is essential for optimal localization of follicular Th cells in the germinal center light zone to promote autoantibody-producing B cells. J. Immunol.191 (4), 1614–1624. 10.4049/jimmunol.1300479
29
DohlmanH. G.SongJ.MaD.CourchesneW. E.ThornerJ. (1996). Sst2, a negative regulator of pheromone signaling in the yeast Saccharomyces cerevisiae: Expression, localization, and genetic interaction and physical association with Gpa1 (the G-protein alpha subunit). Mol. Cell. Biol.16 (9), 5194–5209. 10.1128/MCB.16.9.5194
30
DoiM.MuraiI.KunisueS.SetsuG.UchioN.TanakaR.et al (2016). Gpr176 is a Gz-linked orphan G-protein-coupled receptor that sets the pace of circadian behaviour. Nat. Commun.7, 10583. 10.1038/ncomms10583
31
DrueyK. M.UgurO.CaronJ. M.ChenC. K.BacklundP. S.JonesT. L. (1999). Amino-terminal cysteine residues of RGS16 are required for palmitoylation and modulation of Gi- and Gq-mediated signaling. J. Biol. Chem.274 (26), 18836–18842. 10.1074/jbc.274.26.18836
32
DʼSouzaM. S.GuisingerT. C.NormanH.SeeleyS. L.ChrissobolisS. (2019). Regulator of G-protein signaling 5 protein protects against anxiety- and depression-like behavior. Behav. Pharmacol.30 (8), 712–721. 10.1097/FBP.0000000000000506
33
DuY. S.HuangB. R. (2005). The structure, classification and function of RGS proteins. Sheng Li Ke Xue Jin Zhan36 (3), 215–219.
34
EstesJ. D.ThackerT. C.HamptonD. L.KellS. A.KeeleB. F.PalenskeE. A.et al (2004). Follicular dendritic cell regulation of CXCR4-mediated germinal center CD4 T cell migration. J. Immunol.173 (10), 6169–6178. 10.4049/jimmunol.173.10.6169
35
FaurobertE.HurleyJ. B. (1997). The core domain of a new retina specific RGS protein stimulates the GTPase activity of transducin in vitro. Proc. Natl. Acad. Sci. U. S. A.94 (7), 2945–2950. 10.1073/pnas.94.7.2945
36
FaurobertE.ScottiA.HurleyJ. B.ChabreM. (1999). RET-RGS, a retina-specific regulator of G-protein signaling, is located in synaptic regions of the rat retina. Neurosci. Lett.269 (1), 41–44. 10.1016/s0304-3940(99)00423-1
37
GaoY.HuH.RamachandranS.EricksonJ. W.CerioneR. A.SkiniotisG. (2019). Structures of the rhodopsin-transducin complex: Insights into G-protein activation. Mol. Cell.75 (4), 781–790.e3. e3. 10.1016/j.molcel.2019.06.007
38
GilmanA. G. (1987). G proteins: Transducers of receptor-generated signals. Annu. Rev. Biochem.56, 615–649. 10.1146/annurev.bi.56.070187.003151
39
Grafstein-DunnE.YoungK. H.CockettM. I.KhawajaX. Z. (2001). Regional distribution of regulators of G-protein signaling (RGS) 1, 2, 13, 14, 16, and GAIP messenger ribonucleic acids by in situ hybridization in rat brain. Brain Res. Mol. Brain Res.88 (1-2), 113–123. 10.1016/s0169-328x(01)00038-9
40
GuS.CifelliC.WangS.HeximerS. P. (2009). RGS proteins: Identifying new GAPs in the understanding of blood pressure regulation and cardiovascular function. Clin. Sci.116 (5), 391–399. 10.1042/CS20080272
41
HayasakaN.AokiK.KinoshitaS.YamaguchiS.WakefieldJ. K.Tsuji-KawaharaS.et al (2017). Attenuated food anticipatory activity and abnormal circadian locomotor rhythms in Rgs16 knockdown mice. J. PLoS ONE6 (3), e17655. 10.1371/journal.pone.0017655
42
HayasakaN.AokiK.KinoshitaS.YamaguchiS.WakefieldJ. K.Tsuji-KawaharaS.et al (2011). Attenuated food anticipatory activity and abnormal circadian locomotor rhythms in Rgs16 knockdown mice. PLoS One6 (3), e17655. 10.1371/journal.pone.0017655
43
Hendriks-BalkM. C.PetersS. L. M.MichelM. C.AlewijnseA. E. (2008). Regulation of G protein-coupled receptor signalling: Focus on the cardiovascular system and regulator of G protein signalling proteins. Eur. J. Pharmacol.585 (2-3), 278–291. 10.1016/j.ejphar.2008.02.088
44
HernandezK. R.KarimZ. A.QasimH.DrueyK. M.AlshboolF. Z.KhasawnehF. T. (2019). Regulator of G-protein signaling 16 is a negative modulator of platelet function and thrombosis. J. Am. Heart Assoc.8 (5), e011273. 10.1161/JAHA.118.011273
45
HeximerS. P.WatsonN.LinderM. E.BlumerK. J.HeplerJ. R. (1997). RGS2/G0S8 is a selective inhibitor of Gqalpha function. Proc. Natl. Acad. Sci. U. S. A.94 (26), 14389–14393. 10.1073/pnas.94.26.14389
46
HooksS. B.WaldoG. L.CorbittJ.BodorE. T.KruminsA. M.HardenT. K. (2003). RGS6, RGS7, RGS9, and RGS11 stimulate GTPase activity of Gi family G-proteins with differential selectivity and maximal activity. J. Biol. Chem.278 (12), 10087–10093. 10.1074/jbc.M211382200
47
HoshiY.EndoK.ShirakiharaT.FukagawaA.MiyazawaK.SaitohM. (2016). The potential role of regulator of G-protein signaling 16 in cell motility mediated by δEF1 family proteins. FEBS Lett.590 (2), 270–278. 10.1002/1873-3468.12042
48
HsuH. C.YangP.WangJ.WuQ.MyersR.ChenJ.et al (2008). Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat. Immunol.9 (2), 166–175. 10.1038/ni1552
49
HuX.TangJ.ZengG.BaoP.WuJ.et al (2019). RGS1 silencing inhibits the inflammatory response and angiogenesis in rheumatoid arthritis rats through the inactivation of Toll-like receptor signaling pathway. J. Cell. Physiol.234 (11), 20432–20442. 10.1002/jcp.28645
50
HuY.ZhengM.WangS.GaoL.GouR.LiuO.et al (2021). Identification of a five-gene signature of the RGS gene family with prognostic value in ovarian cancer. Genomics113 (4), 2134–2144. 10.1016/j.ygeno.2021.04.012
51
HuangJ.PashkovV.KurraschD. M.YuK.GoldS. J.WilkieT. M. (2006). Feeding and fasting controls liver expression of a regulator of G protein signaling (Rgs16) in periportal hepatocytes. Comp. Hepatol.5, 8. 10.1186/1476-5926-5-8
52
HuangR.LiG.ZhaoZ.ZengF.ZhangK.LiuY.et al (2020). RGS16 promotes glioma progression and serves as a prognostic factor. CNS Neurosci. Ther.26 (8), 791–803. 10.1111/cns.13382
53
JohnsonE. N.SeasholtzT. M.WaheedA. A.KreutzB.SuzukiN.KozasaT.et al (2003). RGS16 inhibits signalling through the G alpha 13-Rho axis. Nat. Cell. Biol.5 (12), 1095–1103. 10.1038/ncb1065
54
KarimZ. A.AlshboolF. Z.VemanaH. P.ConlonC.DrueyK. M.KhasawnehF. T. (2016). CXCL12 regulates platelet activation via the regulator of G-protein signaling 16. Biochim. Biophys. Acta1863 (2), 314–321. 10.1016/j.bbamcr.2015.11.028
55
KimJ. H.LeeJ. Y.LeeK. T.LeeJ. K.LeeK. H.JangK. T.et al (2010). RGS16 and FosB underexpressed in pancreatic cancer with lymph node metastasis promote tumor progression. Tumour Biol.31 (5), 541–548. 10.1007/s13277-010-0067-z
56
KimK.LeeJ.GhilS. (2018). The regulators of G protein signaling RGS16 and RGS18 inhibit protease-activated receptor 2/Gi/o signaling through distinct interactions with Gα in live cells. FEBS Lett.592 (18), 3126–3138. 10.1002/1873-3468.13220
57
KimS. D.SungH. J.ParkS. K.KimT. W.ParkS. C.et al (2006). The expression patterns of RGS transcripts in platelets. Platelets17 (7), 493–497. 10.1080/09537100600758123
58
KimpleA. J.BoschD. E.GiguereP. M.SiderovskiD. P. (2011). Regulators of G-protein signaling and their Gα substrates: Promises and challenges in their use as drug discovery targets. Pharmacol. Rev.63 (3), 728–749. 10.1124/pr.110.003038
59
KoelleM. R. (1997). A new family of G-protein regulators - the RGS proteins. Curr. Opin. Cell. Biol.9 (2), 143–147. 10.1016/s0955-0674(97)80055-5
60
KoelleM. R.HorvitzH. R. (1996). EGL-10 regulates G protein signaling in the C. elegans nervous system and shares a conserved domain with many mammalian proteins. Cell.84 (1), 115–125. 10.1016/s0092-8674(00)80998-8
61
KozasaT.JiangX.HartM. J.SternweisP. M.SingerW. D.GilmanA. G.et al (1998). p115 RhoGEF, a GTPase activating protein for Galpha12 and Galpha13. Science280 (5372), 2109–2111. 10.1126/science.280.5372.2109
62
KriegerN. S.BushinskyD. A. (2021). Metabolic acidosis regulates RGS16 and G protein signaling in osteoblasts. Am. J. Physiol. Ren. Physiol.321 (4), F424–f430. 10.1152/ajprenal.00166.2021
63
KvebergL.RyanJ. C.RolstadB.InngjerdingenM. (2005). Expression of regulator of G protein signalling proteins in natural killer cells, and their modulation by Ly49A and Ly49D. Immunology115 (3), 358–365. 10.1111/j.1365-2567.2005.02174.x
64
LambrechtB. N.HammadH. (2015). The immunology of asthma. Nat. Immunol.16 (1), 45–56. 10.1038/ni.3049
65
Layeghi-GhalehsoukhtehS.Pal ChoudhuriS.OcalO.ZolghadriY.PashkovV.NiederstrasserH.et al (2020). Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. Sci. Rep.10 (1), 20662. 10.1038/s41598-020-77373-8
66
LeeS. H.LimK. S.HongK. C.KimJ. M. (2021). Genetic association of polymorphisms in porcine RGS16 with porcine circovirus viral load in naturally infected Yorkshire pigs. J. Anim. Sci. Technol.63 (6), 1223–1231. 10.5187/jast.2021.e105
67
LiangG.BansalG.XieZ.DrueyK. M. (2009). RGS16 inhibits breast cancer cell growth by mitigating phosphatidylinositol 3-kinase signaling. J. Biol. Chem.284 (32), 21719–21727. 10.1074/jbc.M109.028407
68
LintermanM. A.RigbyR. J.WongR. K.YuD.BrinkR.CannonsJ. L.et al (2009). Follicular helper T cells are required for systemic autoimmunity. J. Exp. Med.206 (3), 561–576. 10.1084/jem.20081886
69
LippertE.YoweD. L.GonzaloJ. A.JusticeJ. P.WebsterJ. M.FedykE. R.et al (2003). Role of regulator of G protein signaling 16 in inflammation-induced T lymphocyte migration and activation. J. Immunol.171 (3), 1542–1555. 10.4049/jimmunol.171.3.1542
70
LiuT.BohlkenA.KuljacaS.LeeM.NguyenT.SmithS.et al (2005). The retinoid anticancer signal: Mechanisms of target gene regulation. Br. J. Cancer93 (3), 310–318. 10.1038/sj.bjc.6602700
71
MasuhoI.BalajiS.MunteanB. S.SkamangasN. K.ChavaliS.TesmerJ. J. G.et al (2020). A global map of G protein signaling regulation by RGS proteins. Cell.183 (2), 503–521.e19. e19. 10.1016/j.cell.2020.08.052
72
MesinL.ErschingJ.VictoraG. D. (2016). Germinal center B cell dynamics. Immunity45 (3), 471–482. 10.1016/j.immuni.2016.09.001
73
MiedaM.OnoD.HasegawaE.OkamotoH.HonmaK. I.HonmaS.et al (2015). Cellular clocks in AVP neurons of the SCN are critical for interneuronal coupling regulating circadian behavior rhythm. Neuron85 (5), 1103–1116. 10.1016/j.neuron.2015.02.005
74
MiyoshiN.IshiiH.SekimotoM.DokiY.MoriM. (2009). RGS16 is a marker for prognosis in colorectal cancer. Ann. Surg. Oncol.16 (12), 3507–3514. 10.1245/s10434-009-0690-3
75
MumaN. A. (2012). RGS proteins: Impact on the treatment of depression and anxiety. Int. J. Neuropsychopharmacol.15 (9), 1199–1200. 10.1017/S1461145711002008
76
NevesS. R.RamP. T.IyengarR. (2002). G protein pathways. Science296 (5573), 1636–1639. 10.1126/science.1071550
77
O'BrienJ. B.WilkinsonJ. C.RomanD. L. (2019). Regulator of G-protein signaling (RGS) proteins as drug targets: Progress and future potentials. J. Biol. Chem.294 (49), 18571–18585. 10.1074/jbc.REV119.007060
78
OcalO.PashkovV.KolliparaR. K.ZolghadriY.CruzV. H.HaleM. A.et al (2015). A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. Dis. Model. Mech.8 (10), 1201–1211. 10.1242/dmm.020933
79
PerrierP.MartinezF. O.LocatiM.BianchiG.NebuloniM.VagoG.et al (2004). Distinct transcriptional programs activated by interleukin-10 with or without lipopolysaccharide in dendritic cells: Induction of the B cell-activating chemokine, CXC chemokine ligand 13. J. Immunol.172 (11), 7031–7042. 10.4049/jimmunol.172.11.7031
80
RenduF.Brohard-BohnB. (2001). The platelet release reaction: Granules' constituents, secretion and functions. Platelets12 (5), 261–273. 10.1080/09537100120068170
81
RichmanR. W.StrockJ.HainsM. D.CabanillaN. J.LauK. K.SiderovskiD. P.et al (2005). RGS12 interacts with the SNARE-binding region of the Cav2.2 calcium channel. J. Biol. Chem.280 (2), 1521–1528. 10.1074/jbc.M406607200
82
RohJ.ShinS. J.LeeA. N.YoonD. H.SuhC.ParkC. J.et al (2017). RGS1 expression is associated with poor prognosis in multiple myeloma. J. Clin. Pathol.70 (3), 202–207. 10.1136/jclinpath-2016-203713
83
RossD. W.AyscueL. H.WatsonJ.BentleyS. A. (1988). Stability of hematologic parameters in healthy subjects. Intraindividual versus interindividual variation. Am. J. Clin. Pathol.90 (3), 262–267. 10.1093/ajcp/90.3.262
84
RossE. M.WilkieT. M. (2000). GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu. Rev. Biochem.69, 795–827. 10.1146/annurev.biochem.69.1.795
85
Sae-LeeC.MoolsuwanK.ChanL.PoungvarinN. (2016). ChREBP regulates itself and metabolic genes implicated in lipid accumulation in β-cell line. PLoS One11 (1), e0147411. 10.1371/journal.pone.0147411
86
SambiB. S.HainsM. D.WatersC. M.ConnellM. C.WillardF. S.KimpleA. J.et al (2006). The effect of RGS12 on PDGFbeta receptor signalling to p42/p44 mitogen activated protein kinase in mammalian cells. Cell. Signal.18 (7), 971–981. 10.1016/j.cellsig.2005.08.003
87
SchiffM. L.SiderovskiD. P.JordanJ. D.BrothersG.SnowB.De VriesL.et al (2000). Tyrosine-kinase-dependent recruitment of RGS12 to the N-type calcium channel. Nature408 (6813), 723–727. 10.1038/35047093
88
ShankarS. P.WilsonM. S.DiVietroJ. A.Mentink-KaneM. M.XieZ.WynnT. A.et al (2012). RGS16 attenuates pulmonary Th2/Th17 inflammatory responses. J. Immunol.188 (12), 6347–6356. 10.4049/jimmunol.1103781
89
ShiG. X.HarrisonK.HanS. B.MoratzC.KehrlJ. H. (2004). Toll-like receptor signaling alters the expression of regulator of G protein signaling proteins in dendritic cells: implications for G protein-coupled receptor signaling. J. Immunol.172 (9), 5175–5184. 10.4049/jimmunol.172.9.5175
90
ShuF. J.RamineniS.HeplerJ. R. (2010). RGS14 is a multifunctional scaffold that integrates G protein and Ras/Raf MAPkinase signalling pathways. Cell. Signal.22 (3), 366–376. 10.1016/j.cellsig.2009.10.005
91
SiehlerS. (2009). Regulation of RhoGEF proteins by G12/13-coupled receptors. Br. J. Pharmacol.158 (1), 41–49. 10.1111/j.1476-5381.2009.00121.x
92
SierraD. A.GilbertD. J.HouseholderD.GrishinN. V.YuK.UkidweP.et al (2002). Evolution of the regulators of G-protein signaling multigene family in mouse and human. Genomics79 (2), 177–185. 10.1006/geno.2002.6693
93
SjögrenB.BlazerL. L.NeubigR. R. (2010). Regulators of G protein signaling proteins as targets for drug discovery. Prog. Mol. Biol. Transl. Sci.91, 81–119. 10.1016/S1877-1173(10)91004-1
94
SlepK. C.KercherM. A.WielandT.ChenC. K.SimonM. I.SiglerP. B. (2008). Molecular architecture of Galphao and the structural basis for RGS16-mediated deactivation. Proc. Natl. Acad. Sci. U. S. A.105 (17), 6243–6248. 10.1073/pnas.0801569105
95
SnowB. E.AntonioL.SuggsS.SiderovskiD. P. (1998). Cloning of a retinally abundant regulator of G-protein signaling (RGS-r/RGS16): Genomic structure and chromosomal localization of the human gene. Gene206 (2), 247–253. 10.1016/s0378-1119(97)00593-3
96
SnowB. E.HallR. A.KruminsA. M.BrothersG. M.BouchardD.BrothersC. A.et al (1998). GTPase activating specificity of RGS12 and binding specificity of an alternatively spliced PDZ (PSD-95/Dlg/ZO-1) domain. J. Biol. Chem.273 (28), 17749–17755. 10.1074/jbc.273.28.17749
97
SoundararajanM.WillardF. S.KimpleA. J.TurnbullA. P.BallL. J.SchochG. A.et al (2008). Structural diversity in the RGS domain and its interaction with heterotrimeric G protein alpha-subunits. Proc. Natl. Acad. Sci. U. S. A.105 (17), 6457–6462. 10.1073/pnas.0801508105
98
SunX.CharbonneauC.WeiL.ChenQ.TerekR. M. (2015). miR-181a targets RGS16 to promote chondrosarcoma growth, angiogenesis, and metastasis. Mol. Cancer Res.13 (9), 1347–1357. 10.1158/1541-7786.MCR-14-0697
99
SuurväliJ.PahtmaM.SaarR.PaalmeV.NuttA.TiivelT.et al (2015). RGS16 restricts the pro-inflammatory response of monocytes. Scand. J. Immunol.81 (1), 23–30. 10.1111/sji.12250
100
SuurväliJ.RobertJ.BoudinotP.Ruutel BoudinotS. (2013). R4 regulators of G protein signaling (RGS) identify an ancient MHC-linked synteny group. Immunogenetics65 (2), 145–156. 10.1007/s00251-012-0661-x
101
SyrovatkinaV.AlegreK. O.DeyR.HuangX. Y. (2016). Regulation, signaling, and physiological functions of G-proteins. J. Mol. Biol.428 (19), 3850–3868. 10.1016/j.jmb.2016.08.002
102
TanyR.GotoY.KondoY.AokiK. (2022). Quantitative live-cell imaging of GPCR downstream signaling dynamics. Biochem. J.479 (8), 883–900. 10.1042/BCJ20220021
103
TimmuskS.MerlotE.LovgrenT.JarvekulgL.BergM.FossumC. (2009). Regulator of G protein signalling 16 is a target for a porcine circovirus type 2 protein. J. Gen. Virol.90 (10), 2425–2436. 10.1099/vir.0.008896-0
104
UedaH. R.ChenW.AdachiA.WakamatsuH.HayashiS.TakasugiT.et al (2002). A transcription factor response element for gene expression during circadian night. Nature418 (6897), 534–539. 10.1038/nature00906
105
VillasenorA.WangZ. V.RiveraL. B.OcalO.AsterholmI. W.SchererP. E.et al (2010). Rgs16 and Rgs8 in embryonic endocrine pancreas and mouse models of diabetes. Dis. Model. Mech.3 (9-10), 567–580. 10.1242/dmm.003210
106
VivotK.MoulleV. S.ZarroukiB.TremblayC.ManciniA. D.MaachiH.et al (2016). The regulator of G-protein signaling RGS16 promotes insulin secretion and β-cell proliferation in rodent and human islets. Mol. Metab.5 (10), 988–996. 10.1016/j.molmet.2016.08.010
107
WalkerL. S.WiggettH. E.GaspalF. M. C.RaykundaliaC. R.GoodallM. D.ToellnerK. M.et al (2003). Established T cell-driven germinal center B cell proliferation is independent of CD28 signaling but is tightly regulated through CTLA-4. J. Immunol.170 (1), 91–98. 10.4049/jimmunol.170.1.91
108
WalshT. G.HarperM. T.PooleA. W. (2015). SDF-1α is a novel autocrine activator of platelets operating through its receptor CXCR4. Cell. Signal.27 (1), 37–46. 10.1016/j.cellsig.2014.09.021
109
WangD.YuH.ZhouX.LiuX.ZhangR.LuZ.et al (2019). Author Correction: Probing the crystallographic orientation of two-dimensional atomic crystals with supramolecular self-assembly. Nat. Commun.41 (1), 165–177. 10.1038/s41467-018-08077-x
110
WangJ.DucretA.TuY.KozasaT.AebersoldR.RossE. M. (1998). RGSZ1, a Gz-selective RGS protein in brain. Structure, membrane association, regulation by Galphaz phosphorylation, and relationship to a Gz gtpase-activating protein subfamily. J. Biol. Chem.273 (40), 26014–26025. 10.1074/jbc.273.40.26014
111
WangJ.HuaT.LiuZ. J. (2020). Structural features of activated GPCR signaling complexes. Curr. Opin. Struct. Biol.63, 82–89. 10.1016/j.sbi.2020.04.008
112
WangY.HoG.ZhangJ. J.NieuwenhuijsenB.EdrisW.ChandaP. K.et al (2002). Regulator of G protein signaling Z1 (RGSZ1) interacts with Galpha i subunits and regulates Galpha i-mediated cell signaling. J. Biol. Chem.277 (50), 48325–48332. 10.1074/jbc.M206116200
113
WeisshaarN.WuJ.MingY.MadiA.Hotz-WagenblattA.MaS.et al (2022). Rgs16 promotes antitumor CD8(+) T cell exhaustion. Sci. Immunol.7 (71), eabh1873. 10.1126/sciimmunol.abh1873
114
WiechecE.OvergaardJ.HansenL. L. (2008). A fragile site within the HPC1 region at 1q25.3 affecting RGS16, RGSL1, and RGSL2 in human breast carcinomas. Genes. Chromosom. Cancer47 (9), 766–780. 10.1002/gcc.20578
115
WiechecE.WiufC.OvergaardJ.HansenL. L. (2011). High-resolution melting analysis for mutation screening of RGSL1, RGS16, and RGS8 in breast cancer. Cancer Epidemiol. Biomarkers Prev.20 (2), 397–407. 10.1158/1055-9965.EPI-10-0514
116
WillardF. S.WillardM. D.KimpleA. J.SoundararajanM.OestreichE. A.LiX.et al (2009). Regulator of G-protein signaling 14 (RGS14) is a selective H-Ras effector. PLoS One4 (3), e4884. 10.1371/journal.pone.0004884
117
XieS.LiJ.WangJ. H.WuQ.YangP.HsuH. C.et al (2010). IL-17 activates the canonical NF-kappaB signaling pathway in autoimmune B cells of BXD2 mice to upregulate the expression of regulators of G-protein signaling 16. J. Immunol.184 (5), 2289–2296. 10.4049/jimmunol.0903133
118
XieX.LvH.LiuC.SuX.YuZ.SongS.et al (2021). HBeAg mediates inflammatory functions of macrophages by TLR2 contributing to hepatic fibrosis. BMC Med.19 (1), 247. 10.1186/s12916-021-02085-3
119
XieZ.ChanE. C.DrueyK. M. (2016). R4 regulator of G protein signaling (RGS) proteins in inflammation and immunity. Aaps J.18 (2), 294–304. 10.1208/s12248-015-9847-0
120
YoweD.WeichN.PrabhudasM.PoissonL.ErradaP.KapellerR.et al (2001). RGS18 is a myeloerythroid lineage-specific regulator of G-protein-signalling molecule highly expressed in megakaryocytes. Biochem. J.359 (1), 109–118. 10.1042/0264-6021:3590109
121
ZhangY.HigginsC. B.FortuneH. M.ChenP.StothardA. I.MayerA. L.et al (2019). Hepatic arginase 2 (Arg2) is sufficient to convey the therapeutic metabolic effects of fasting. Nat. Commun.10 (1), 1587. 10.1038/s41467-019-09642-8
122
ZhangY.NeoS. Y.HanJ.YawL. P.LinS. C. (1999). RGS16 attenuates galphaq-dependent p38 mitogen-activated protein kinase activation by platelet-activating factor. J. Biol. Chem.274 (5), 2851–2857. 10.1074/jbc.274.5.2851
123
ZhengB.ChenD.FarquharM. G. (2000). MIR16, a putative membrane glycerophosphodiester phosphodiesterase, interacts with RGS16. Proc. Natl. Acad. Sci. U. S. A.97 (8), 3999–4004. 10.1073/pnas.97.8.3999
124
ZolghadriY.Pal ChoudhuriS.OcalO.Layeghi-GhalehsoukhtehS.BerheF.HaleM. A.et al (2018). Malnutrition in pancreatic ductal adenocarcinoma (PDA): Dietary pancreatic enzymes improve short-term health but stimulate tumor growth. Am. J. Pathol.188 (3), 616–626. 10.1016/j.ajpath.2017.11.014
Summary
Keywords
RGS16, GPCR, immunity, inflammation, tumor, metabolic disorders
Citation
Tian M, Ma Y, Li T, Wu N, Li J, Jia H, Yan M, Wang W, Bian H, Tan X and Qi J (2022) Functions of regulators of G protein signaling 16 in immunity, inflammation, and other diseases. Front. Mol. Biosci. 9:962321. doi: 10.3389/fmolb.2022.962321
Received
06 June 2022
Accepted
08 August 2022
Published
02 September 2022
Volume
9 - 2022
Edited by
Venkateswarlu Kanamarlapudi, Swansea University Medical School, United Kingdom
Reviewed by
Vsevolod V Gurevich, Vanderbilt University, United States
Marcel Bermudez, University of Münster, Germany
Updates
Copyright
© 2022 Tian, Ma, Li, Wu, Li, Jia, Yan, Wang, Bian, Tan and Qi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jianni Qi, slqijn@126.com; Xu Tan, tanxu20210501@126.com
This article was submitted to Cellular Biochemistry, a section of the journal Frontiers in Molecular Biosciences
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.